ZBH — Zimmer Biomet Holdings, Inc. stock price, charts and financials

Latest market price

95.81

-1.17-1.21%

Overview Short InterestFilings

ZBHQT54Zimmer Biomet Holdings, Inc.·NYSE

Overview Short InterestFilings

95.81-1.21%

Earnings

Down 1.2% — Reported earnings — EPS beat by 12%, revenue in line.

High confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PHG+0.92%$26.47 SNN-5.32%$30.44 PEN+0.37%$324.22 ALGN+0.22%$173.27 PODD-1.70%$166.82 GMED+0.06%$81.51 RMD+3.69%$223.14 DXCM-0.42%$86.94

Snapshot

Index	S&P 500	P/E	24.89	EPS (ttm)	3.85	Insider Own	0.30%	Shs Outstand	193.46M	Perf Week	0.06%

Market Cap	18.54B	Forward P/E	10.64	EPS next Y	9.01	Insider Trans	-1.49%	Shs Float	193.11M	Perf Month	6.74%

Enterprise Value	25.58B	PEG	3.61	EPS next Q	-	Inst Own	-	Short Float	6.24%	Perf Quarter	15.89%

Income	762.00M	P/S	2.20	EPS this Y	120.45%	Inst Trans	-	Short Ratio	4.98	Perf Half Y	11.12%

Sales	8.41B	P/B	1.46	EPS next Y	6.12%	ROA	3.35%	Short Interest	12.05M	Perf YTD	6.55%

Book/sh	65.51	P/C	43.72	EPS next 5Y	6.90%	ROE	6.01%	52W High	108.28 -11.52%	Perf Year	5.73%

Cash/sh	2.19	P/FCF	9.90	EPS past 3/5Y	47.78% -	ROIC	5.26%	52W Low	79.12 21.09%	Perf 3Y	-31.24%

Dividend Est.	0.96 (1.00%)	EV/EBITDA	11.60	Sales past 3/5Y	5.86% 6.08%	Gross Margin	70.03%	Volatility	2.46% 2.81%	Perf 5Y	-39.35%

Dividend TTM	0.96 (1.00%)	EV/Sales	3.04	EPS Y/Y TTM	-13.09%	Oper. Margin	15.61%	ATR (14)	3.01	Perf 10Y	-19.93%

Dividend Ex-Date	Jun 25, 2026	Quick Ratio	0.95	Sales Y/Y TTM	9.51%	Profit Margin	9.05%	RSI (14)	58.66	Recom	2.67

Dividend Gr. 3/5Y	0.00% 0.59%	Current Ratio	1.73	EPS Q/Q	15.47%	SMA20	3.96%	Beta	0.46	Target Price	96.57

Payout	24.88%	Debt/Eq	0.59	Sales Q/Q	9.32%	SMA50	7.47%	Rel Volume	1.54	Prev Close	96.98

Employees	17,000	LT Debt/Eq	0.55	Earnings	Aug 05	SMA200	5.19%	Avg Volume	2.30M	Price	95.81

IPO Date	Jul 25, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.05% 0.78%	Net Debt/EBITDA	3.19	Volume	3,547,096	Change	-1.21%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-28-26	Reiterated	UBS	Sell	$89 → $115
Jul-09-26	Downgrade	BMO Capital	Outperform → Market Perform	$95
Apr-29-26	Reiterated	Canaccord Genuity	Hold	$93 → $83
Apr-29-26	Reiterated	Stifel Nicolaus	Buy	$110 → $105
Apr-29-26	Reiterated	Robert W. Baird		$100 → $92
Apr-29-26	Reiterated	Truist Securities	Hold	$101 → $92
Apr-29-26	Reiterated	Barclays	Underweight	$100 → $94
Mar-23-26	Downgrade	BTIG	Buy → Neutral
Feb-12-26	Reiterated	Barclays	Underweight	$105 → $100
Feb-11-26	Reiterated	UBS	Sell	$86 → $89

Latest News

Aug-04-26

Aug-04-2609:51AM

Can These 3 MedTech Stocks Hit Targets This Earnings Season?zacks.com

Jul-29-26

Jul-29-2610:01AM

Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?zacks.com

Jul-28-26

Jul-28-2607:39PM

Sector Update: Healthcare Stocks Gain Late AfternoonYahoo

07:42AM

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More247wallst.com

Jul-27-26

Jul-27-2603:54AM

Gabelli Funds LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net

Jul-26-26

Jul-26-2604:09AM

ABN Amro Investment Solutions Sells 15,516 Shares of Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net

Jul-21-26

Jul-21-2606:43PM

ISRG Stock: The Math Hidden In Its PriceYahoo

10:41AM

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Termzacks.com

04:18AM

D.A. Davidson & CO. Has $2.67 Million Stake in Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net

Jul-14-26

Jul-14-2606:06PM

The Paid-To-Hold Play On ISRG Stock: A 12% IncomeYahoo

07:00AM

Zimmer Biomet Names Chintan Desai President of Asia Pacific Regionprnewswire.com

Jul-13-26

Jul-13-2607:30AM

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Resultsprnewswire.com

Jul-10-26

Jul-10-2603:11PM

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?zacks.com

Jul-07-26

Jul-07-2604:21PM

How Big Is the Appendectomy Opportunity for ISRG's Robotic Expansion?Yahoo

Jul-02-26

Jul-02-2610:40AM

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?zacks.com

Company

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	8,409	8,232	7,679	7,394	6,940	6,827	6,128	7,982	7,933
Cost of Goods Sold Incl. D&A	2,519	3,160	2,191	2,084	2,020	1,960	1,824	2,253	2,272
Gross Profit	5,889	5,072	5,487	5,310	4,920	4,867	4,303	5,730	5,661
Selling, General and Administrative Excl. Other	3,343	3,251	2,930	2,839	2,762	2,843	2,713	3,344	3,379
Research and Development	451	459	437	459	406	436	323	449	392
Other Operating Expense	783	0	835	735	1,056	728	1,184	799	1,856
Operating Income	1,312	1,362	1,286	1,278	696	860	83	1,138	34
Interest Expense	295	293	218	201	165	208	212	227	289
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-114	-239	-31	-9	-128	-153	24	-5	-16
Net Income Before Taxes	903	831	1,037	1,067	404	499	-105	906	-271
Income Taxes	142	126	131	42	112	54	-96	-226	108
Consolidated Net Income	762	705	904	1,024	231	402	-139	1,132	-379
Net Income From Continuing Operations	760	705	905	1,025	291	446	-9	1,132	-379
Net Income	762	705	904	1,024	231	402	-139	1,132	-379
EPS (Recurring)	3.87	3.56	4.45	4.91	1.10	1.93	-0.67	5.52	-1.86
EPS (Basic, Before Extraordinaries)	3.87	3.56	4.45	4.91	1.10	1.93	-0.67	5.52	-1.86
EPS (Diluted)	3.85	3.55	4.43	4.88	1.10	1.91	-0.67	5.47	-1.86
EBITDA	2,206	2,217	2,251	2,220	1,495	1,645	1,005	2,139	1,059
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	24.89	25.33	23.84	24.94	115.91	64.52	—	26.55	—
Price To Sales Ratio	2.22	2.16	2.79	3.44	3.86	3.77	5.05	3.73	2.59
Gross Margin	70.03	61.61	71.45	71.81	70.89	71.29	70.22	71.79	71.36
Operating Margin	15.60	16.55	16.75	17.28	10.03	12.60	1.35	14.26	0.43
Net Margin	9.06	8.56	11.77	13.85	3.33	5.89	-2.27	14.18	-4.78
Shares Outstanding	195	198	203	209	210	209	207	205	204
Market Capitalization	18,683	17,804	21,443	25,435	26,775	25,757	30,944	29,768	20,526
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thornal Kevin R	Grp Pres-Global Business	Aug 01 '26	Option Exercise	0.00	9,957	0	9,957	Aug 04
Yi Sang	Group President, Asia Pacific	May 29 '26	Sale	82.64	5,000	413,216	27,251	Jun 02
Noor Jehanzeb	See remarks below.	Apr 01 '26	Option Exercise	0.00	6,626	0	6,828	Apr 03
Winkler Lori	SVP and CHRO	Mar 12 '26	Sale	94.66	2,650	250,849	10,224	Mar 16
Upadhyay Suketu	Exec VP, CFO	Mar 06 '26	Option Exercise	0.00	14,776	0	71,514	Mar 10
VAN ZUILEN WILFRED	Group Pres, EMEA	Mar 06 '26	Option Exercise	0.00	7,004	0	31,553	Mar 10
Winkler Lori	SVP and CHRO	Mar 06 '26	Option Exercise	0.00	5,634	0	13,503	Mar 10
Yi Sang	Group President, Asia Pacific	Mar 06 '26	Option Exercise	0.00	9,414	0	32,251	Mar 10
Stellato Paul A	VP, Controller, CAO	Mar 06 '26	Option Exercise	0.00	1,970	0	5,890	Mar 10
Phipps Chad F	See remarks below.	Mar 06 '26	Option Exercise	0.00	6,786	0	68,603	Mar 10
Tornos Ivan	Chairman, President and CEO	Mar 06 '26	Option Exercise	0.00	34,704	0	92,118	Mar 10
VAN ZUILEN WILFRED	Group Pres, EMEA	Feb 25 '26	Option Exercise	0.00	3,182	0	26,637	Feb 27
Phipps Chad F	See remarks below.	Feb 25 '26	Option Exercise	0.00	2,626	0	64,763	Feb 27
Yi Sang	Group President, Asia Pacific	Feb 25 '26	Option Exercise	0.00	2,785	0	22,837	Feb 27
Winkler Lori	SVP and CHRO	Feb 25 '26	Option Exercise	0.00	2,347	0	10,342	Feb 27

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.